c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

Molecular Carcinogenesis

Volumn 55, Issue 11, 2016, Pages 1678-1687

  Byeon, Hyung Kwon ^a   Na, Hwi Jung ^a   Yang, Yeon Ju ^a   Kwon, Hyeong Ju ^a   Chang, Jae Won ^b   Ban, Myung Jin ^c   Kim, Won Shik ^a   Shin, Dong Yeob ^a   Lee, Eun Jig ^a   Koh, Yoon Woo ^a   Yoon, Joo Heon ^a   Choi, Eun Chang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

drug resistance; molecular targeted therapy; mutation; thyroid neoplasm drug therapy

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; VEMURAFENIB; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MET PROTEIN, HUMAN; SULFONAMIDE; SULFONE;

ANAPLASTIC THYROID CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME REACTIVATION; EXPERIMENTAL MODEL; IN VIVO STUDY; MALE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CANCER CELL LINE; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; THYROID NEOPLASMS; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SULFONAMIDES; SULFONES; THYROID NEOPLASMS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84950161799     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22418     Document Type: Article

References (22)

1. Cancer Institute. SEERNational Stat Fact Sheet: Thyroid Cancer. Available at: http://seer.cancer.gov/statfacts/html/thyro.html. Accessed October 28, 2013.
2. Thyroid Cancer page. National Cancer Institute, Web site. Available at: http://www.cancer.gov/cancertopics/types/thyroid. Accessed January 18, 2010.
3. Lal G, O'Dorisio T, McDougall R, Weigel RJ. Cancer of the endocrine system In: Abeloff MD, Armitage JO, Niedernuber JE, Kastan MB, McKenna WG, editors. Abeloff's clinical oncology. 4th ed. Philadelphia, PA: Churchill Livingston; 2008. chap 75.
4. Prinz RA, Chen E. Thyroid Cancer In: Bope ET, Rakel RE, Kellerman RD, editors. Conn's current therapy 2010. Maryland Heights, MO: W. B. Saunders, Elsevier; 2009.
5. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013; 368:684–685.
6. Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 2013; 123:1059–1064.
7. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399–5404.
8. Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 2007; 96:1549–1553.
9. Hall RD, Kudchadkar RR. BRAF mutations: Signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Control 2014; 21:221–230.
10. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507–2516.
11. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366:2038–2040.
12. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28:15s.
13. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012; 18:2056–2065.
14. Girotti MR, Marais R. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov 2013; 3:487–490.
15. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: A potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004; 10:2761–2765.
16. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454–1457.
17. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: A new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004; 89:2867–2872.
18. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245–262.
19. Lee J, Hwang JA, Lee EK. Recent progress of genome study for anaplastic thyroid cancer. Genomics Inform 2013; 11:68–75.
20. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2:227–235.
21. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500–504.
22. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013; 3:520–533.